The results highlight the importance of evaluating and monitoring cognitive function in individuals with recent critical illness or major infections, especially if they are already at risk for dementia.
Low-dose naproxen increases frequency of adverse health effects and does not reduce progression of presymptomatic Alzheimer disease in cognitively intact persons at risk.
Use of the orally administered β-site amyloid precursor protein-cleaving enzyme 1 inhibitors, verubecestat and atabecestat, does not prevent clinical progression to Alzheimer disease.
Gerontologists, practicing ethicists, policymakers, and health practitioners should consider the structural conditions of long-term care that both foster aggression and constrain prevention efforts, according to this commentary.
Memantine monotherapy was associated with a 7% lower risk for any cardiovascular event compared with both acetylcholinesterase inhibitor monotherapy and combination therapy, according to a new study.
The development of levodopa-induced dyskinesia (LID) appears to correlate with cognitive decline, as well as with the development of Parkinson disease (PD) dementia, researchers found. The findings from this study were published in Neurology. A total of 119 patients with PD who were treated with levodopa for more than 5 years were included in this…
